These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 8445942)
1. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942 [TBL] [Abstract][Full Text] [Related]
2. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968 [TBL] [Abstract][Full Text] [Related]
3. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
4. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918 [TBL] [Abstract][Full Text] [Related]
5. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371 [TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749 [TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. Kalaycio M; Pohlman B; Elson P; Lichtin A; Hussein M; Tripp B; Andresen S Am J Clin Oncol; 2001 Feb; 24(1):58-63. PubMed ID: 11232951 [TBL] [Abstract][Full Text] [Related]
9. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574 [TBL] [Abstract][Full Text] [Related]
10. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
11. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021 [TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536 [TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533 [TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614 [TBL] [Abstract][Full Text] [Related]
16. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688 [TBL] [Abstract][Full Text] [Related]
17. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Bernell P; Kimby E; Hast R Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158 [TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
19. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial. He XY; Elson P; Pohlman B; Lichtin A; Hussein M; Andresen S; Kalaycio M BMC Cancer; 2002 May; 2():12. PubMed ID: 12019034 [TBL] [Abstract][Full Text] [Related]
20. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]